HIMS Stock Forecast & Price Target

Hims & Hers Health is projected to experience significant revenue growth, with international revenue expected to rise from approximately $50 million in FY25 to nearly $1 billion by FY30, driven by an expansion of treatment options and geographical reach. Moreover, core US revenue is anticipated to grow annually by about 21%, primarily fueled by a substantial subscriber increase and enhanced revenue per subscriber through personalized services and premium treatment offerings. The ongoing trend towards private healthcare, particularly in the UK, further supports favorable market conditions for Hims & Hers, as consumer demand for alternative healthcare solutions increases.

Hims & Hers Health has demonstrated volatility in its stock performance, having more than doubled year-to-date but subsequently losing over 20% since late July, primarily due to concerns about slowing core growth. Key financial risks include slower adoption of personalized treatments, potential regulatory impacts on its business model, challenges in sustaining revenue growth while driving operating leverage, and intensified competition within the digital health sector. These factors collectively contribute to a negative outlook for the company's financial stability and long-term growth prospects.